Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Lyell Immunopharma, Inc. presented at the H.C. Wainwright 4th Annual BioConnect Investor Conference. CEO Lynn Seely discussed the company's initiatives in the CD19/20 space and colorectal cancer. The presentation included an overview of current data and future plans.
- ▪Lyell Immunopharma, Inc. is focused on advancing therapies in the CD19/20 space.
- ▪The company is actively working on initiatives related to colorectal cancer.
- ▪Lynn Seely, the CEO, provided insights into the company's current data and future strategies.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908145-lyell-immunopharma-inc-lyel-presents-at-h-c-wainwright-4th-annual-bioconnect-investor"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
